DocketNumber: 18-1010
Judges: Brian H. Corcoran
Filed Date: 9/30/2020
Status: Non-Precedential
Modified Date: 9/30/2020
In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS No. 18-1010V UNPUBLISHED BANGALORE MUNIRAJU, Chief Special Master Corcoran Petitioner, Filed: August 28, 2020 v. Special Processing Unit (SPU); Joint SECRETARY OF HEALTH AND Stipulation on Damages; Tetanus HUMAN SERVICES, Diphtheria acellular Pertussis (Tdap) Vaccine; Influneza (Flu) Vaccine; Respondent. Guillain-Barre Syndrome (GBS) William E. Cochran, Jr., Black McLaren Jones Ryland & Griffee, P.C., Memphis, TN , for petitioner. Alexis B. Babcock, U.S. Department of Justice, Washington, DC, for respondent. DECISION ON JOINT STIPULATION 1 On July 13, 2018, Bangalore Muniraju filed a petition for compensation under the National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq. 2 (the “Vaccine Act”). Petitioner alleges that he suffered Guillain-Barre Syndrome (GBS) as a result of his September 27, 2017 influneza (“flu”) and Tetanus Diphtheria acellular Pertussis (“Tdap”) vaccinations. Petition at 1; Stipulation, filed at August 26, 2020, ¶¶ 1, 2, 4. Petitioner further alleges that the vaccinations were administered within the United States, that he suffered the residual effects of his injury for more than six months, and that there has been no prior award or settlement of a civil action on his behalf as a result of his injury. Stipulation at ¶¶ 3-5; see Petition at ¶¶2, 17. “Respondent denies that the Tdap or flu vaccines caused petitioner to suffer from a Table injury of GBS, Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”), or any other injury or his current condition.” Stipulation at ¶ 6. 1 Because this unpublished decision contains a reasoned explanation for the action in this case, I am required to post it on the United States Court of Federal Claims' website in accordance with the E- Government Act of 2002.44 U.S.C. § 3501
note (2012) (Federal Management and Promotion of Electronic Government Services). This means the decision will be available to anyone with access to the internet. In accordance with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information, the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that the identified material fits within this definition, I will redact such material from public access. 2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660,100 Stat. 3755
. Hereinafter, for ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa (2012). Nevertheless, on August 26, 2020, the parties filed the attached joint stipulation, stating that a decision should be entered awarding compensation. I find the stipulation reasonable and adopt it as my decision awarding damages, on the terms set forth therein. Pursuant to the terms stated in the attached Stipulation, I award the following compensation: a. A lump sum of $888,373.24, which amount represents compensation for first year life care expenses ($11,345.16), lost earnings ($725,760.08), pain and suffering ($150,000.00) and past unreimbursable expenses ($1,268.00) in the form of a check payable to Petitioner; and b. An amount sufficient to purchase the annuity contract described in paragraph 10 of the Stipulation, paid to the life insurance company from which the annuity will be purchased (the "Life Insurance Company"). Stipulation at ¶ 8. This amount represents compensation for all items of damages that would be available under Section 15(a). Id. I approve the requested amount for Petitioner’s compensation. In the absence of a motion for review filed pursuant to RCFC Appendix B, the clerk of the court is directed to enter judgment in accordance with this decision. 3 IT IS SO ORDERED. s/Brian H. Corcoran Brian H. Corcoran Chief Special Master 3 Pursuant to Vaccine Rule 11(a), entry of judgment can be expedited by the parties’ joint filing of notice renouncing the right to seek review. 2